| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.TUBE.2015.05.004 |
| P698 | PubMed publication ID | 26073894 |
| P2093 | author name string | Charles J Eyermann | |
| Disha Awasthy | |||
| Sreevalli Sharma | |||
| Vasan K Sambandamurthy | |||
| Anisha Ambady | |||
| Naina Vinay Mudugal | |||
| Sudha Ravishankar | |||
| Umender K Sharma | |||
| Vasanthi Ramachandran | |||
| Folkert Reck | |||
| Gayathri Balakrishnan | |||
| Supreeth Guptha | |||
| Suresh Rudrapatna | |||
| Radha Nandishaiah | |||
| Sandesh Jatheendranath | |||
| Sreenivasaiah Menasinakai | |||
| P2860 | cites work | High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism | Q21131409 |
| DNA topoisomerases: structure, function, and mechanism | Q22065417 | ||
| Genes required for mycobacterial growth defined by high density mutagenesis | Q27976512 | ||
| Repair of and checkpoint response to topoisomerase I-mediated DNA damage | Q28187875 | ||
| DNA topoisomerases and their poisoning by anticancer and antibacterial drugs | Q28284744 | ||
| Characterization of DNA topoisomerase I from Mycobacterium tuberculosis: DNA cleavage and religation properties and inhibition of its activity. | Q54325202 | ||
| A homogeneous, high-throughput fluorescence anisotropy-based DNA supercoiling assay. | Q54377994 | ||
| Crystal Structure of Full Length Topoisomerase I from Thermotoga maritima | Q57013543 | ||
| Escherichia coli DNA topoisomerase I mutants: Increased supercoiling is corrected by mutations near gyrase genes | Q67265169 | ||
| The creation of a camptothecin-sensitive Escherichia coli based on the expression of the human topoisomerase I | Q70913046 | ||
| Electroporation at elevated temperatures substantially improves transformation efficiency of slow-growing mycobacteria | Q71807398 | ||
| Conditional silencing of topoisomerase I gene of Mycobacterium tuberculosis validates its essentiality for cell survival | Q95561966 | ||
| Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium | Q28378889 | ||
| Essentiality and functional analysis of type I and type III pantothenate kinases of Mycobacterium tuberculosis | Q28486611 | ||
| CarD is an essential regulator of rRNA transcription required for Mycobacterium tuberculosis persistence | Q28486907 | ||
| Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis | Q28659633 | ||
| In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice | Q28909142 | ||
| Drugs for bad bugs: confronting the challenges of antibacterial discovery | Q29547723 | ||
| Nonreplicating persistence of mycobacterium tuberculosis | Q29615312 | ||
| New use of BCG for recombinant vaccines | Q29615313 | ||
| Use of a flexible cassette method to generate a double unmarked Mycobacterium tuberculosis tlyA plcABC mutant by gene replacement | Q29619839 | ||
| Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection | Q34006776 | ||
| On the viability of Escherichia coli cells lacking DNA topoisomerase I | Q34175610 | ||
| Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. | Q34214929 | ||
| Depletion of antibiotic targets has widely varying effects on growth | Q34651942 | ||
| Identification of anziaic acid, a lichen depside from Hypotrachyna sp., as a new topoisomerase poison inhibitor | Q34674078 | ||
| New alkaloid antibiotics that target the DNA topoisomerase I of Streptococcus pneumoniae | Q34675643 | ||
| Protein inactivation in mycobacteria by controlled proteolysis and its application to deplete the beta subunit of RNA polymerase. | Q34723636 | ||
| Synthesis and antibacterial evaluation of anziaic acid and analogues as topoisomerase I inhibitors | Q35074386 | ||
| Mutation adjacent to the active site tyrosine can enhance DNA cleavage and cell killing by the TOPRIM Gly to Ser mutant of bacterial topoisomerase I. | Q36457138 | ||
| Controlling gene expression in mycobacteria | Q36895683 | ||
| Structural studies of type I topoisomerases | Q37108394 | ||
| Bacterial topoisomerase I as a target for discovery of antibacterial compounds | Q37108422 | ||
| Multidrug-resistant and extensively drug-resistant tuberculosis: a review | Q37315209 | ||
| Structure and mechanism of action of type IA DNA topoisomerases | Q37704425 | ||
| In-vitro activity of pristinamycin and its components against gram-negative anaerobic bacilli and Gardnerella vaginalis | Q37898243 | ||
| New drugs for the treatment of tuberculosis: hope and reality | Q38023907 | ||
| Isolation of the topB gene encoding DNA topoisomerase III as a multicopy suppressor of topA null mutations in Escherichia coli | Q38316571 | ||
| 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial | Q39580496 | ||
| Bacterial cell killing mediated by topoisomerase I DNA cleavage activity | Q41456897 | ||
| Identifying vulnerable pathways in Mycobacterium tuberculosis by using a knockdown approach | Q41849520 | ||
| Development of a repressible mycobacterial promoter system based on two transcriptional repressors | Q41902289 | ||
| Characterization of the Haemophilus influenzae topA locus: DNA topoisomerase I is required for genetic competence | Q42630376 | ||
| Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo. | Q42708475 | ||
| Overexpression of type I topoisomerases sensitizes yeast cells to DNA damage | Q43608431 | ||
| Polycations increase the permeability of Mycobacterium vaccae cell envelopes to hydrophobic compounds | Q43751002 | ||
| Escherichia coli DNA topoisomerase I mutants have compensatory mutations in DNA gyrase genes. | Q44244250 | ||
| Pristinamycin-inducible gene regulation in mycobacteria. | Q46018412 | ||
| Viability of Escherichia coli topA mutants lacking DNA topoisomerase I. | Q50095510 | ||
| Overexpression of the Shigella flexneri genes coding for DNA topoisomerase IV compensates for loss of DNA topoisomerase I: effect on virulence gene expression | Q50145028 | ||
| Isolation and characterization of a topA mutant of Shigella flexneri | Q50166730 | ||
| Roles of the two type II NADH dehydrogenases in the survival of Mycobacterium tuberculosis in vitro. | Q51703604 | ||
| Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis. | Q53052343 | ||
| Deciphering the distinct role for the metal coordination motif in the catalytic activity of Mycobacterium smegmatis topoisomerase I. | Q53372825 | ||
| P433 | issue | 5 | |
| P921 | main subject | Mycobacterium tuberculosis | Q130971 |
| P304 | page(s) | 589-598 | |
| P577 | publication date | 2015-05-27 | |
| P1433 | published in | Tuberculosis | Q15757844 |
| P1476 | title | Genetic and chemical validation identifies Mycobacterium tuberculosis topoisomerase I as an attractive anti-tubercular target | |
| P478 | volume | 95 |
| Q37318987 | A novel proposal of a simplified bacterial gene set and the neo-construction of a general minimized metabolic network |
| Q28547068 | An IPTG Inducible Conditional Expression System for Mycobacteria |
| Q58763717 | Characterization of new, efficient Mycobacterium tuberculosis topoisomerase-I inhibitors and their interaction with human ABC multidrug transporters |
| Q89647207 | Covalent Complex of DNA and Bacterial Topoisomerase: Implications in Antibacterial Drug Development |
| Q93381258 | Direct observation of topoisomerase IA gate dynamics |
| Q48180953 | Discovery of novel bacterial topoisomerase I inhibitors by use of in silico docking and in vitro assays. |
| Q46315911 | Distinct Mechanism Evolved for Mycobacterial RNA Polymerase and Topoisomerase I Protein-Protein Interaction. |
| Q28552724 | Essentiality Assessment of Cysteinyl and Lysyl-tRNA Synthetases of Mycobacterium smegmatis |
| Q52684515 | Evidence for Inhibition of Topoisomerase 1A by Gold(III) Macrocycles and Chelates Targeting Mycobacterium tuberculosis and Mycobacterium abscessus. |
| Q36535308 | Insights from the Structure of Mycobacterium tuberculosis Topoisomerase I with a Novel Protein Fold |
| Q89113641 | Investigating mycobacterial topoisomerase I mechanism from the analysis of metal and DNA substrate interactions at the active site |
| Q64115105 | Mechanism and resistance for antimycobacterial activity of a fluoroquinophenoxazine compound |
| Q35999091 | Small-Molecule Inhibitors Targeting Topoisomerase I as Novel Antituberculosis Agents |
| Q36149725 | Synthesis, evaluation, and CoMFA study of fluoroquinophenoxazine derivatives as bacterial topoisomerase IA inhibitors. |
| Q46478240 | Targeting DNA Replication and Repair for the Development of Novel Therapeutics against Tuberculosis |
| Q38855273 | Targeting bacterial topoisomerases: how to counter mechanisms of resistance |
Search more.